Date
2019Journal
BMC Medical Informatics and Decision MakingPublisher
BioMed Central Ltd.Type
article
Metadata
Show full item recordAbstract
Background: Vaccination has been one of the most successful public health interventions to date, and the U.S. FDA/CDC Vaccine Adverse Event Reporting System (VAERS) currently contains more than 500,000 reports for post-vaccination adverse events that occur after the administration of vaccines licensed in the United States. The VAERS dataset is huge, contains very large dimension nominal variables, and is complex due to multiple listing of vaccines and adverse symptoms in a single report. So far there has not been any statistical analysis conducted in attempting to identify the cross-board patterns on how all reported adverse symptoms are related to the vaccines. Methods: For studies of the relationship between vaccines and reported adverse events, we consider a partial VAERS dataset which includes all reports filed over a period of 24 years between 1990-2013. We propose a neighboring method to process this dataset for dealing with the complications caused by multiple listing of vaccines and adverse symptoms in a single report. Then, the combined approaches based on our neighboring method and novel utilization of data visualization techniques are employed to analyze the large dimension dataset for characterization of the cross-board patterns of the relations between all reported vaccines and events. Results: The results of our analysis indicate that those events or symptoms with overall high occurrence frequencies are positively correlated, and those most frequently occurred adverse symptoms are mostly uncorrelated or negatively correlated under different bacteria vaccines, but they are in many cases positively correlated under different virus vaccines, especially under flu vaccines. No particular patterns are shown under live vs. inactive vaccines. Conclusions: This article identifies certain cross-board patterns of the relationship between the vaccines and the reported adverse events or symptoms. This helps for better understanding the VAERS data, and provides a useful starting point for the development of statistical models and procedures to further analyze the VAERS data. Copyright 2019 The Author(s).Sponsors
Professor Ren's research was partially supported by the National Science Foundation (NSF) of USA grant DMS-1407461; Professor He's research was partially supported by National Institutes of Health (NIH) of USA NIH-NIAID grant R01A1081062; Professor Zhang's research was partially supported by NIH grants P30-CA13274 and U24-HL134763.Keyword
Bacteria vaccineCorrelation coefficient matrix
Data visualization
Inactivated vaccine
Live vaccine
Neighboring method
Virus vaccine
Identifier to cite or link to this item
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85066399292&doi=10.1186%2fs12911-019-0818-8&partnerID=40&md5=919e1471ed26cdde28581dc95decfb1b; http://hdl.handle.net/10713/10253ae974a485f413a2113503eed53cd6c53
10.1186/s12911-019-0818-8
Scopus Count
Collections
Related articles
- Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
- Authors: Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, Haber P, Pless RP, Mootrey G, Ellenberg SS, Braun MM, Chen RT
- Issue date: 2003 Jan 24
- Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine.
- Authors: Wattigney WA, Mootrey GT, Braun MM, Chen RT
- Issue date: 2001 May
- Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).
- Authors: Shimabukuro TT, Nguyen M, Martin D, DeStefano F
- Issue date: 2015 Aug 26
- Understanding vaccine safety information from the Vaccine Adverse Event Reporting System.
- Authors: Varricchio F, Iskander J, Destefano F, Ball R, Pless R, Braun MM, Chen RT
- Issue date: 2004 Apr
- Elective termination of pregnancy after vaccination reported to the Vaccine Adverse Event Reporting System (VAERS): 1990-2006.
- Authors: Chang S, Ball R, Braun MM
- Issue date: 2008 May 2
Related items
Showing items related by title, author, creator and subject.
-
Early smallpox vaccine manufacturing in the United States: Introduction of the "animal vaccine" in 1870, establishment of "vaccine farms", and the beginnings of the vaccine industryEsparza, J.; Lederman, S.; Nitsche, A. (Elsevier Ltd, 2020)For the first 80-90 years after Jenner's discovery of vaccination in 1796, the main strategy used to disseminate and maintain the smallpox vaccine was arm-to-arm vaccination, also known as Jennerian or humanized vaccination. A major advance occurred after 1860 with the development of what was known as "animal vaccine", which referred to growing vaccine material from serial propagation in calves before use in humans. The use of "animal vaccine" had several advantages over arm-to-arm vaccination: it would not transmit syphilis or other human diseases, it ensured a supply of vaccine even in the absence of the spontaneous occurrence of cases of cowpox or horsepox, and it allowed the production of large amounts of vaccine. The "animal vaccine" concept was introduced in the United States in 1870 by Henry Austin Martin. Very rapidly a number of "vaccine farms" were established in the U.S. and produced large quantities of "animal vaccine". These "vaccine farms" were mostly established by medical doctors who saw an opportunity to respond to an increasing demand of smallpox vaccine from individuals and from health authorities, and to make a profit. The "vaccine farms" evolved from producing only smallpox "animal vaccine" to manufacturing several other biologics, including diphtheria- and other antitoxins. Two major incidents of tetanus contamination happened in 1901, which led to the promulgation of the Biologics Control Act of 1902. The US Secretary of the Treasury issued licenses to produce and sell biologicals, mainly vaccines and antitoxins. Through several mergers and acquisitions, the initial biologics licensees eventually evolved into some of the current major American industrial vaccine companies. An important aspect that was never clarified was the source of the vaccine stocks used to manufacture the smallpox "animal vaccines". Most likely, different smallpox vaccine stocks were repeatedly introduced from Europe, resulting in polyclonal vaccines that are now recognized as "variants" more appropriately than "strains". Further, clonal analysis of modern "animal vaccines" indicate that they are probably derived from complex recombinational events between different strains of vaccinia and horsepox. Modern sequencing technologies are now been used by us to study old smallpox vaccine specimens in an effort to better understand the origin and evolution of the vaccines that were used to eradicate the smallpox. Copyright 2020 The Author(s)
-
Evaluation of a booster dose of pentavalent rotavirus vaccine coadministered with measles, yellow fever, and meningitis a Vaccines in 9-Month-old malian infantsTapia, Milagritos D.; Sow, Samba O.; Fitzpatrick, Meagan; Neuzil, Kathleen M.; Kotloff, Karen L. (Oxford University Press, 2018-07-13)Background Rotavirus vaccines given to infants are safe and efficacious. A booster dose of rotavirus vaccine could extend protection into the second year of life in low-resource countries. Methods We conducted an open-label, individual-randomized trial in Bamako, Mali. We assigned 600 infants aged 9-11 months to receive measles vaccine (MV), yellow fever vaccine (YFV), and meningococcal A conjugate vaccine (MenAV) with or without pentavalent rotavirus vaccine (PRV). We assessed the noninferiority (defined as a difference of ≤10%) of seroconversion and seroresponse rates to MV, YFV, and MenAV. We compared the seroresponse to PRV. Results Seroconversion to MV occurred in 255 of 261 PRV recipients (97.7%) and 246 of 252 control infants (97.6%; difference, 0.1% [95% confidence interval {CI}, -4.0%-4.2%]). Seroresponse to YFV occurred in 48.1% of PRV recipients (141 of 293), compared with 52.2% of controls (153 of 293; difference, -4.1% [95% CI, -12.2%-4.0%]). A 4-fold rise in meningococcus A bactericidal titer was observed in 273 of 292 PRV recipients (93.5%) and 276 of 293 controls (94.2%; difference, -0.7% [95% CI, -5.2%-3.8%]). Rises in geometric mean concentrations of immunoglobulin A and immunoglobulin G antibodies to rotavirus were higher among PRV recipients (118 [95% CI, 91-154] and 364 [95% CI, 294-450], respectively), compared with controls (68 [95% CI, 50-92] and 153 [95% CI, 114-207], respectively). Conclusions PRV did not interfere with MV and MenAV; this study could not rule out interference with YFV. PRV increased serum rotavirus antibody levels. Clinical Trials Registration NCT02286895. © The Author(s) 2018.
-
Evaluation of a Booster Dose of Pentavalent Rotavirus Vaccine Coadministered with Measles, Yellow Fever, and Meningitits A Vaccines in 9-month-old Malian InfantsHaidara, Fadima C.; Tapia, Milagritos D.; Sow, Samba O. (Oxford University Press, 2018)